Intensity Therapeutics, Inc. INTS
Intensity Therapeutics, Inc. (Nasdaq: INTS) is an oncology drug developer. Its lead program, INT230-6, is in Phase 3 for soft tissue sarcoma (second- and third-line treatment). Its next catalyst on record is INT230-6 in triple-negative breast cancer (INVINCIBLE-4): IDMB review update on skin irritation resolution (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: INT230-6 in triple-negative breast cancer (INVINCIBLE-4) — IDMB review update on skin irritation resolution (Q1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| INT230-6 | soft tissue sarcoma (second- and third-line) | small molecule | Phase 3 |
| INT230-6 | triple-negative breast cancer (localized) | small molecule | Phase 2 |
| INT230-6 | early-stage breast cancer (presurgical monotherapy) | small molecule | Phase 2 |
Recent results and decisions
- Aug 11, 2026positive Preliminary INVINCIBLE-4 data from 14 patients showed 71% pCR with INT230-6 plus SOC versus 42% with SOC alone and 44% reduction in grade 3 adverse events.
Preliminary data from the first 14 patients (seven in each cohort) showed a 71% pathological complete response in patients receiving INT230-6 in Cohort A and a 42% pCR in patients receiving the SOC alone (Cohort B).
Filing - started In July 2026, Intensity restarted patient treatment in the Phase 2 INVINCIBLE-4 Study in triple negative breast cancer after a September 2025 pause.
In July 2026, the Company restarted patient treatment in the INVINCIBLE-4 Study and is currently targeting complete enrollment by the end of 2027.
Filing - May 7, 2026positive Preliminary INVINCIBLE-4 data (reported March 2026): pCR in 5/7 (71.4%) INT230-6 patients vs 2/6 (33%) on standard of care alone; 44% fewer grade 3+ AEs.
Preliminary observations of the INVINCIBLE-4 Study showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to SOC (“Cohort A”) achieved a pathological complete response ("pCR") whereas two (2) out of six (6) (33%) patients in the SOC arm alone (“Cohort B”) achieved a pCR,
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.